KORU Medical Systems, Inc. (KRMD)
(Delayed Data from NSDQ)
$4.16 USD
+0.12 (2.97%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.17 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRMD 4.16 +0.12(2.97%)
Will KRMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRMD
Are You Looking for a Top Momentum Pick? Why KORU Medical Systems, Inc. (KRMD) is a Great Choice
KORU Medical Systems, Inc. (KRMD) Reports Break-Even Earnings for Q2
KRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
American Well Corporation (AMWL) Reports Q2 Loss, Beats Revenue Estimates
Omnicell (OMCL) Beats Q2 Earnings and Revenue Estimates
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
Other News for KRMD
Is KRMD poised for gains? Crossed Above 20 Day Moving Average shows up after advancing 2.97%
Craig-Hallum Reaffirms Their Buy Rating on REPRO-MED Systems (KRMD)
Is KRMD consolidating before a move? Bollinger Band Squeeze shows up after rising 2.02%
REPRO-MED Systems (KRMD) Receives a Buy from Canaccord Genuity
Lake Street Reaffirms Their Buy Rating on REPRO-MED Systems (KRMD)